A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (Brain Tumors)
Sponsor: |
NIH |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT8904 |
U.S. Govt. ID: |
NCT04729959 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most people get for recurrent glioblastoma.
Investigator
Fabio Iwamoto, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with glioblastoma (GBM)? |
Yes |
No |
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? |
Yes |
No |